ABSTRACT Previous work has shown that mammalian cells that carry unstably amplified genes for dihydrofolate reductase (DHFR) gradually lose the amplified DHFR genes when grown in the absence of the DHFR inhibitor methotrexate (MTX). Unstably amplified genes occur on small acentric chromosomes called double minutes (DMs) or even smaller chromatin fragments, in contrast to stably amplified genes, which reside in centromerecontaining chromosomes. We have found that the rate of loss of the unstably amplified DHFR genes can be greatly increased by growing the cells in the presence of a nonlethal concentration of hydroxyurea. For example, in one MTX-resistant subline studied, =90% of the original DHFR gene dosage is lost in 25-30 cell doublings in the absence of MTX. The same degree of loss is achieved, however, in <4 doublings if cells are grown in the presence of 50 pM hydroxyurea. This new effect of hydroxyurea does not appear to be due to changes in plating efficiency or selective cytotoxicity.
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In particular, no increase in cell death occurs at 50 JIM hydroxyurea, and cells continue to multiply, albeit '/2 to 2/3 as fast as in the absence of hydroxyurea. The ability to selectively accelerate the loss of amplified genes from mammalian cells as shown in the present work may have important implications both for the problem of drug resistance in cancer chemotherapy and for curing mammalian cells of extrachromosomally maintained DNA genomes of pathogenic viruses.
Mammalian cells have been shown to acquire resistance to a dihydrofolate reductase (DHFR) inhibitor, methotrexate (MTX), either through an amplification of the DHFR gene, which leads to overproduction of the target DHFR enzyme (1) (2) (3) (4) (5) (6) (7) , through mutations rendering the DHFR enzyme less sensitive to MTX, or through mutations decreasing MTX uptake by cells (1) . Of these causes of MTX resistance, DHFR gene amplification appears to be the most frequent one under a variety of experimental conditions (1) (2) (3) (4) (5) (6) (7) .
Amplified chromosomal regions other than the DHFR gene domain also occur in a wide variety of eukaryotic cells, usually as a result of in vivo or in vitro selection for specific properties, such as tumorigenicity (5, 6, 8) or resistance to a cytotoxic drug (1, 7, 9) , but also in the course of normal development (10) .
Amplified chromosomal regions occur either within the major cellular chromosomes where they are frequently recognizable as karyotypic abnormalities called "homogeneously staining regions" or as small acentric chromosomes called "double minutes" (DMs) (1, (8) (9) (10) (11) . Unlike stably amplified genes in homogeneously staining regions, which are retained for many generations in the absence of a relevant selection pressure, the unstably amplified genes in acentric DMs or smaller chromatin fragments are gradually lost from cells in the absence of selection pressure, at least in part because of the absence of functioning centromeres in DMs (1) (2) (3) (4) (5) (6) 11) .
It was recently reported that phorbol 12-myristate 13-acetate (PMA), a noncytotoxic, nonmutagenic phorbol ester tumor promoter, greatly increases the incidence of mouse cells with amplified DHFR genes under conditions of cytotoxic selection for resistance to MTX (4) . Subsequent work by Tlsty et al. (12) has confirmed this result and in addition showed that transient cytotoxic treatment of mammalian cells (with hydroxyurea or ultraviolet light) before selection for MTX resistance also leads to an increased incidence of cells with amplified DHFR genes (12, 13) . Noncytotoxic tumor promoters other than PMA as well as mitogenic hormones, such as insulin or epidermal growth factor, have also been shown recently to greatly increase the incidence of MTX resistance due to DHFR gene amplification (14) . These findings have provided indirect support for an earlier hypothesis that one pathway of carcinogenesis and tumor progression may operate through a generalized increase in the frequency of disproportionate DNA replication, resulting in accelerated gene amplification (15) . Targets for such "facilitated" gene amplification may include genes responsible for the initial stages of carcinogenesis or other genetic loci-for example, genes influencing metastatic potential or immunosuppressive properties of evolving tumor cells (5, 6, 8, 11, (15) (16) (17) . Regardless of which of the suggested mechanisms of facilitated gene amplification is the correct one, it is clear that the probability of either gene amplification per se or survival of "nascent" cells bearing amplified genes can vary dramatically at least in vitro, depending on the conditions of selection (4, (12) (13) (14) .
In several situations (for example, in cancer chemotherapy), one would like to minimize the probability of either the emergence or the persistence of cells with undesirable amplified genes. One way to approach this problem is to look for ways to increase the probability of loss of already amplified genes and to do so under otherwise noncytotoxic conditions.
We report here that when mouse cells bearing unstably amplified DHFR The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. the P*-globin cDNA probe. Dots c5, c8, and cli a loading (data not shown). Dots al-fl and a7-f7: Dh dosages, respectively, for R.3 cells at the time of rei containing 0.3 IA4 MTX. Dots a2-a6 and a7-a12 gene dosages, respectively, for the MTX-sensitive ("single-copy" control forDHFR). For the remainin 8-12 represent DHFR and globin gene dosages, r DNA Isolation and DNADNA Dot Hybridization. Cell monolayers were rinsed with 0.14 M NaCl/5 mM Na Hepes (pH 7.5), then scraped with a rubber policeman into 0.5% Nonidet P-40/5 mM Na2EDTA/5 mM Na Hepes, pH 7.5. The lysate was homogenized by four strokes of a Dounce homogenizer with a loose-fitting pestle and then centrifuged at 2,000 X g for 5 min. Purification of DNA from the pellet of crude nuclei was carried out as described (4) . In some experiments DNA was purified in parallel from both whole cells and isolated nuclei. Cell-population doubling times were deduced from the number of cells initially seeded and the number of cells at confluence at each passage. Relative dosage of the DHFR gene (defined as a ratio of the DHFR copy number in MTX-resistant cells to that in MTX-sensitive unselected 3T6 cells) was determined by a DNA-DNA dot-blot hybridization as described (4, 18) (Fig. 1 ). An important criterion used in the search for such an agent was that its effective concentration had to be nonlethal for cells on prolonged exposure. Therefore the concentration of each of the compounds to be tested in the DHFR gene loss assay ( Fig. 1) was first optimized by growing the cells for a number of generations in the presence of different concentrations of the compound to be tested and then choosing the concentration that neither increased cell death nor slowed cell multiplication more than 2-fold (Fig. 2) . Hydroxyurea, which happened to be the third agent tested, produced a striking effect (Figs. 1 and 3 DHFR gene dosage was lost in less than four cell doublings (first passage in MTX-free medium) (Fig. 1A) . Similar results were obtained with another line of MTX-resistant cells, R500 (a gift from R. Kaufman (Fig. 4A) . The larger surface area of cells grown in 50 AM hydroxyurea is due to a hydroxyurea-mediated metabolic disturbance that leads to an increased cell volume (30) .
The concentration of hydroxyurea used throughout this work (50 ,M) was chosen to maximize the rate of DHFR gene loss without decreasing cell viability and only moderately decreasing growth rate of cells (Fig. 2) . Concentrations of hydroxyurea significantly below 50 AM were much less effective in accelerating the loss of the DHFR genes (Fig. 3) . On the other hand, concentrations of hydroxyurea significantly higher than 50 pM do result in significant cytotoxicity after prolonged exposure (data not shown). (Fig. 4A) . The striking effect of hydroxyurea on the rate of loss of the DHFR genes from cells in the course of this single-passage experiment is shown in Fig.  4B . Considering the ways in which unstably amplified genes are thought to be lost from cells (1) (2) (3) (4) (5) (6) , it is interesting that the DHFR gene dosage in the hydroxyurea-treated cells continued to decrease between days 10 and 12, a period when the cells are at the plateau of their growth curve ( Fig. 4B; cf. Fig. 4A ).
Rate of Hydroxyurea-Accelerated DHFR Gene Loss from R500 Cells Is the Same Whether Measured with Nuclear or Whole Cell DNA Samples. To see if the hydroxyurea effect is due to an increased probability of postmitotic partitioning of DHFR gene-containing DMs into the cytoplasm through formation of micronuclei [a known pathway of DM loss (1)], we have monitored the DHFR gene dosage decrease at low cellpopulation doublings using both nuclear and whole cell DNA samples in a series of parallel measurements. The results obtained (Fig. 5) clearly did not significantly depend on the way DNA was isolated (either from crude nuclei or from whole cells). Although the data of Fig. 5 are consistent with "nonpartitioning" mechanisms of the hydroxyurea effect, they are insufficient to preclude the "partitioning" mechanisms, because several interpretations (for example, cosedimentation of nuclei and micronuclei in our preparations or rapid in vitro degradation of what possible uses could this new effect be put to?
The absence of significant cytotoxicity of 50 ,tM hydroxyurea toward cells from lines bearing widely different numbers of amplified DHFR genes (see above) argues strongly against any mechanism for the hydroxyurea effect in which hydroxyurea preferentially suppresses growth of those cells that have higher than average numbers of the amplified DHFR genes.
One possible mechanism of the hydroxyurea effect may operate by increasing the probability of postmitotic partitioning of DHFR gene-containing DMs into the cytoplasm through formation of micronuclei [a known pathway of DM loss (1) (2) (3) (4) (5) (6) ]. Although our results are compatible with such a partitioning mechanism, they add a constraint that the micronuclear DHFR DNA in the cytoplasmic compartment should be degraded rapidly in vivo to account for indistinguishable results of monitoring the DHFR gene loss with either nuclear or whole-cell DNA samples (Fig. 5) .
Other possibilities are that hydroxyurea preferentially inhibits replication [or decatenation (32) ] of unstably amplified DHFR genes or induces their preferential degradation. Although it is likely that the gene loss-enhancing effect of hydroxyurea is mediated by its specific inhibition of the enzyme ribonucleoside diphosphate reductase (33, 34) , a component of the replication fork (35) , no direct evidence is available on this point. Use of other specific inhibitors of ribonucleoside diphosphate reductase (36) is one way to address this question. Furthermore, it is likely that unstably amplified genes other than DHFR are also subject to accelerated loss in the presence of hydroxyurea.
Transient treatments of mammalian cells with cytotoxic concentrations of hydroxyurea are known to increase the frequency of the DHFR gene amplification, apparently by increasing the probability of disproportionate DNA replication (12, 13); a possible relationship of this phenomenon to the new effect of nonlethal hydroxyurea concentrations on the frequency of loss of the DHFR genes remains to be investigated.
Although hydroxyurea is a widely used antineoplastic drug, it is not understood why it is relatively effective for certain cancers, such as chronic granulocytic leukemia or polycythemia vera (37) , but not for many other malignant tumors. Concentrations of hydroxyurea in patients' tissues considered to be therapeutically useful (cytotoxic) are at least an order of magnitude higher than the hydroxyurea concentration used in the present work (50 ILM) (37) . Hydroxyurea is also known to be a potent teratogen (38, 39) . Because transient amplification of specific genes has been shown to constitute a part of normal development in at least some of the higher eukaryotic species (10) , and because many cancers are known to be associated with gene amplification (1, 4-8, 39 ), the new effect of hydroxyurea described above may be relevant to both teratogenic and antineoplastic activities of hydroxyurea.
What are the potential applications of the ability to selectively accelerate the loss of unstably amplified genes from mammalian cells?
Previous studies have shown that the incidence of cells bearing amplified genes under conditions of cytotoxic selection can vary more than 100-fold and depends on either the presence of mitogenic substances (hormones or tumor promoters) during selection (4, 14) or a pre-exposure of cells to certain cytotoxic agents before selection (12, 13) . Emergence of drug-resistant tumor cells during cytotoxic chemotherapy is one of the major unsolved problems in cancer therapy. One potential way to decrease the incidence of gene amplification-mediated drug resistance is to selectively accelerate the loss of newly acquired unstably amplified genes from "nascent" drug-resistant cells.
Unlike amplified cellular genes in tumor cells, which may be either stably or unstably amplified, chromosomes of certain DNA viruses that transform mammalian cells exist virtually exclusively in a free (unintegrated) form (40, 41) . Among such viruses are papilloma viruses and possibly certain types of Herpesvirus (40) . These viruses are associated with a wide variety of human pathologic conditions including both benign and malignant neoplastic lesions (40, 41) .
If hydroxyurea should affect the stability of extrachromosomal viral DNAs in a way analogous to its striking effect on unstably amplified cellular genes, one could exploit the hydroxyurea effect for "curing" mammalian cells of extrachromosomally maintained viral DNA genomes. It should be noted in this regard that Turek et al. (40) have already shown that prolonged treatment of papilloma virus-transformed mouse cells with interferon results in a significant decrease in the number of extrachromosomal viral genomes per cell.
